HealthcareAIGuy says the two drugs earned about four times the AI labs' combined revenue, while only around 2% of people with obesity worldwide take them.
Recap by typeshit. Post by @HealthcareAIGuy on X.
Access to Ozempic, Wegovy and Mounjaro in Australia often comes down to who can pay, raising the question of public subsidies.
The analysis points to CagriSema filings, a DKK 15b buyback and Wegovy pill capacity, while flagging margin pressure and flat 2026 guidance as risks.
Canada is one of the first big markets where semaglutide goes off patent. IQVIA plans ongoing updates on pricing, coverage and generic uptake.
The estimate, shared by M Mohan, starts from about $141 billion in 2025, with North America holding roughly 62% and semaglutide and tirzepatide leading.
Among the items: Walmart plans free GLP-1 diabetes drugs for employees in 2027, and Verdiva Bio dropped a phase II oral GLP-1 study citing market changes.
MedPage Today
A JAMA Network Open analysis of Reddit posts also lists fatigue, insomnia and muscle symptoms. MedPage's roundup adds a CagriSema menopause analysis and Walmart's GLP-1 coverage plan.
Loading…